Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2025 08:45 ET | Source: Wellcome Leap Inc.

Wellcome Leap and Pivotal Commit $100 Million to Women’s Health Research to Deliver Breakthroughs in Years, Not Decades

SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Wellcome Leap, a U.S. non-profit, and Pivotal, a group of organizations founded by Melinda French Gates, today announced a $100 million partnership to...
September 09, 2025 10:30 ET | Source: AstuteAnalytica India Pvt. Ltd.

United States Cell Culture Supplements Market to Worth Over US$ 2,491.6 Million by 2033 | Astute Analytica

Chicago, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The U.S. cell culture supplements market was valued at US$ 835.9 million in 2024 and is expected to reach US$ 2,491.6 million by 2033, growing at a CAGR...
August 20, 2025 12:30 ET | Source: AstuteAnalytica India Pvt. Ltd.

Human Osteoblasts Market to Reach US$ 87.1 Million by 2033 | Astute Analytica

Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global human osteoblasts market was valued at US$ 48.2 million in 2024 and is expected to reach US$ 87.1 million by 2033 at a CAGR of 6.8% during the...
August 18, 2025 09:10 ET | Source: SpringWorks Therapeutics, Inc.

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted...
August 04, 2025 16:15 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

-CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the...
July 18, 2025 11:30 ET | Source: SpringWorks Therapeutics, Inc.

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted...
July 02, 2025 11:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer Approval based on pivotal Phase 1/2 LINKER-MM1...
June 12, 2025 01:00 ET | Source: Biogen Inc.

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue,...
June 10, 2025 07:00 ET | Source: Inteleos, Inc.

e Sono and POCUS Certification Academy Launch Ultrasound Proficiency On-Demand Bundles for Key Clinical and Specialty Certifications

Case-based online ultrasound simulation provides a streamlined path to earning trusted credentials and improving patient care globally.
June 02, 2025 01:00 ET | Source: Sandoz Group

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable...